Daniel L. Kisner - Jun 14, 2022 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc. (ZYNE)

Role
Director
Signature
/s/ Albert P. Parker, Attorney-in-Fact
Stock symbol
ZYNE
Transactions as of
Jun 14, 2022
Transactions value $
-$40
Form type
4
Date filed
6/16/2022, 09:53 PM
Previous filing
Jun 3, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYNE Common Stock Award $0 +23.1K +462.18% $0.00 28.1K Jun 14, 2022 Direct F1
transaction ZYNE Common Stock Sale -$40 -40 -0.14% $1.01 28.1K Jun 14, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYNE Stock Option (right to buy) Award $0 +34.7K $0.00 34.7K Jun 14, 2022 Common Stock 34.7K $1.01 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.
F2 This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
F3 The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.